Analyzing Rennova Health (OTCMKTS:RNVA) & Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and Rennova Health (OTCMKTS:RNVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Profitability

This table compares Enovis and Rennova Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-52.69%	8.74%	4.19%
Rennova Health	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Enovis and Rennova Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	0	7	0	2.75
Rennova Health	0	0	0	0	0.00

Enovis currently has a consensus target price of $47.43, suggesting a potential upside of 86.80%. Given Enovis’ stronger consensus rating and higher possible upside, research analysts clearly believe Enovis is more favorable than Rennova Health.

Insider and Institutional Ownership

98.5% of Enovis shares are owned by institutional investors. 2.7% of Enovis shares are owned by company insiders. Comparatively, 55.5% of Rennova Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Enovis has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Rennova Health has a beta of 22.86, meaning that its share price is 2,186% more volatile than the S&P 500.

Earnings and Valuation

This table compares Enovis and Rennova Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.65	-$1.18 billion	($20.71)	-1.23
Rennova Health	$18.69 million	0.00	-$7.73 million	N/A	N/A

Rennova Health has lower revenue, but higher earnings than Enovis.

Summary

Enovis beats Rennova Health on 7 of the 11 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Rennova Health

Rennova Health, Inc., together with its subsidiaries, provides health care services in the United States. It owns one operating hospital in Oneida, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company is based in West Palm Beach, Florida.